Skip to main content
. 2023 Oct 31;15(21):5248. doi: 10.3390/cancers15215248

Figure 4.

Figure 4

(A) Kaplan–Meier curves for overall survival after initiation of molecular targeting agents among patients with indicated driver oncogene mutations. The Kaplan–Meier survival curves showing OS outcomes for patients treated with molecular targeting agents, categorized based on the presence of specific driver oncogene mutations. The subgroups include ALK, BRAF, EGFR, MET, and ROS1. Notably, no statistical difference was observed in OS among the various subgroups, despite the limited number of patients in some categories. (B) Kaplan–Meier curves for overall survival after initiation of anti-cancer systemic therapy among patients without driver oncogene mutations or not evaluated for mutations. The Kaplan–Meier survival curves for two distinct patient groups: those who were not evaluated for driver oncogene mutations (“NE”) and those without any detected mutations (“No mutation”). Median survival times and 95% confidence intervals are given for each group. The figure highlights the significantly superior OS outcomes for patients who were evaluated and found to have no driver oncogene mutations, compared to those not evaluated (p = 0.021).